4 papers in the library · 4 citations · publishing 2022-2026
BMC Psychiatry March 17, 2026 Bernhard T Baune, Kevin Rosemann, Dimitri Hefter et al. 2 citations
Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.
European Archives of Psychiatry and Clinical Neuroscience July 1, 2025 Erhan Kavakbasi, Kevin Rosemann, Mert Yilmaz et al. 2 citations
Intranasal esketamine (ESK) is a novel therapy option in patients with treatment-resistant depression (TRD). Patients with a history of electroconvulsive therapy (ECT) non-response (ECT+) in the current episode have usually been excluded from previous studies. Data on the effectiveness of ESK in ECT non-responders are sparse. In this retrospective study, we investigated the effectiveness of...
European Psychiatry August 27, 2024 Erhan Kavakbasi, M. Yilmaz, Ö. Bulut et al.
Introduction Esketamine intranasal spray has been approved in both the USA and EU as a novel treatment in patients with treatment-resistant major depression (TRD) and for the management of acute depressive emergencies during the course of major depressive disorder (MDD). Real-world data on the effectiveness and safety of esketamine nasal spray in clinical use are limited. Objectives To...
European Psychiatry June 1, 2022 Bernhard T Baune, Z. Susam, V. Falcone et al.
Introduction Psychiatric emergencies in Major Depressive Disorder (MDD) are characterised by multiple types of symptoms including risk of self-harm and suicidal ideation. S-ketamine intranasally (Spravato) has recently been shown to help alleviate symptoms during depressive emergencies. In this case-series, we detail the clinical effects and usability of S-ketamine applied intranasally in a...